checkAd

     101  0 Kommentare Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - Seite 2

    For additional information:

    Marianne Lambertson (investors & media)
    NLS Pharmaceutics Ltd.
    +1 239.682.8500
    ml@nls-pharma.com
    www.nlspharmaceutics.com

    ###

    Lesen Sie auch

    SOURCE: NLS Pharmaceutics AG



    View the original press release on accesswire.com


    The NLS Pharmaceutics Stock at the time of publication of the news with a fall of -5,83 % to 0,339USD on Nasdaq stock exchange (09. März 2024, 02:00 Uhr).

    Aktuelle Themen


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 2 von 2

    Verfasst von Accesswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - Seite 2 ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for …